References
- 1. K. D. Rainsford, Fifty years since the discovery of ibuprofen, Inflammopharmacol.19 (2011) 293–297; https://doi.org/10.1007/s10787-011-0103-7
- 2. M. De Martino, A. Chiarugi, A. Boner, G. Montini and L. de’ Angelis, Working towards an appropriate use of ibuprofen in children: An evidence-based appraisal, Drugs77 (2017) 1295–1311; https://doi.org/10.1007/s40265-017-0751-z.
- 3. H. Hao, G. Wang and Sun, Enantioselective pharmacokinetics of ibuprofen and involved mechanisms, Drug Metab. Rev. 37 (2005) 215–234; https://doi.org/10.1081/DMR-200047999
- 4. K. D. Rainsford, Ibuprofen: pharmacology, efficacy and safety, Inflammopharmacol.17 (2009) 275–342; https://doi.org/10.1007/s10787-009-0016-x
- 5. G. Ding, Y. Liu, J. Sun, Y. Takeuchi, T. Toda, T. Hayakawa, S. Fukushima, S. Kishimoto, W. Lin and Inotsume, Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans, J. Pharm. Pharmacol.59 (2007) 1509–13; https://doi.org/10.1211/jpp.59.11.0007
- 6. T. J. Legg, A. L. Laurent, R. Leyva and D. Kellstein, Ibuprofen sodium is absorbed faster than standard Ibuprofen tablets: results of two open-label, randomized, crossover pharmacokinetic studies, Drugs R.D.14 (2014) 283–290; https://doi.org/10.1007/s40268-014-0070-8
- 7. F. Jamali and D. R. Brocks, The Pharmacokinetics of Ibuprofen in Humans and Animals, in Ibuprofen (Ed. K. Rainsford), 1st ed., John Wiley & Sons, New York 2015, pp. 81–131; https://doi.org/10.1002/9781118743614.ch4
- 8. S. C. Tan, B. K. Patel, S. H. Jackson, C. G. Swift and A. J. Hutt, Stereoselectivity of ibuprofen metabolism and pharmacokinetics following the administration of the racemate to healthy volunteers, Xenobiotica32 (2002) 683–697; https://doi.org/10.1080/00498250210142994
- 9. J. Kirchheiner, I. Meineke, G. Freytag, C. Meisel, I. Roots and J. Brockmöller, Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2, Clin. Pharmacol. Ther.72 (2002) 62–75; https://doi.org/10.1067/mcp.2002.125726
- 10. S. Y. Chang, W. Li, S. C. Traeger, B. Wang, D. Cui, H. Zhang, B. Wen and A. D. Rodrigues, Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(−)-ibuprofen hydroxylation in vitro, Drug Metab. Dispos. 36 (2008) 2513–2522; https://doi.org/10.1124/dmd.108.022970
- 11. A. D. Rodrigues, Impact of CYP2C9 genotype on pharmacokinetics: Are all cyclooxygenase inhibitors the same? Drug Metab. Dispos.33 (2005) 1567–1575; https://doi.org/10.1124/dmd.105.006452
- 12. F. Mazhar, N. Haider, J. Sultana, S. Akram and Y. Ahmed, Prospective study of NSAIDs prescribing in Saudi Arabia: Cardiovascular and gastrointestinal risk in patients with diabetes mellitus, Int. J. Clin. Pharmacol. Ther.56 (2018) 64–71; https://doi.org/10.5414/CP203071
- 13. O. O. Moninuola, W. Milligan, P. Lochhead and H. Khalili, Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation, Aliment. Pharmacol. Ther.47 (2018) 1428–1439; https://doi.org/10.1111/apt.14606
- 14. A. Pilotto, D. Seripa, M. Franceschi, C. Scarcelli, D. Colaizzo, E. Grandone, V. Niro, A. Andriulli, G. Leandro, F. Di Mario and B. Dallapiccola, Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms, Gastroenterology133 (2007) 465–471; https://doi.org/10.1124/dmd.105.006452
- 15. G. S. Pazhayattil and A. C. Shirali, Drug-induced impairment of renal function, Int. J. Nephrol. Renovasc. Dis.7 (2014) 457–468, https://doi.org/10.2147/IJNRD.S39747
- 16. G. V. Rollason, C. F. Samer, Y. Daali and J. A. Desmeules, Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti-inflammatory drugs: a review, Curr. Drug Metab.15 (2014) 326–343; https://doi.org/10.2174/1389200215666140202214454
- 17. U. Yasar, S. Lundgren, E. Eliasson, A. Bennet, B. Wiman, U. de Faire and A. Rane, Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms, BiochemBiophysResCommun.299 (2002) 25–28; https://doi.org/10.1016/S0006-291X(02)02592-5
- 18. W. C. Speed, S. P. Kang, D. P. Tuck, L. N. Harris and K. K. Kidd, Global variation in CYP2C8-CYP2C9 functional haplotypes, Pharmacogenomics J.9 (2009) 283–290; https://doi.org/10.1038/tpj.2009.10
- 19. T. S. Tracy, A. S. Chaudhry, B. Prasad, K. E. Thummel, E. G. Schuetz, X. B. Zhong, Y. C. Tien, H. Jeong, X. Pan, L. M. Shireman, J. Tay-Sontheimer and Y. S. Lin, Interindividual variability in cytochrome P450-mediated drug metabolism, Drug Metab. Dispos. 44 (2016) 343–351; https://doi.org/10.1124/dmd.115.067900
- 20. J. Kirchheiner and J. Brockmöller, Clinical consequences of cytochrome P450 2C9 polymorphisms, Clin. Pharmacol. Ther. 77 (2005) 1–16; https://doi.org/10.1016/j.clpt.2004.08.009
- 21. A. S. Chaudhry, R. K. Thirumaran, K. Yasuda, X. Yang, Y. Fan, S. C. Strom and E. G. Schuetz, Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s, Drug Metab. Dispos. 41 (2013) 1538–1547; https://doi.org/10.1124/dmd.113.051672
- 22. T. M. Penning, The aldo-keto reductases (AKRs): Overview, Chem. Biol. Interact.234 (2015) 236–246; https://doi.org/10.1016/j.cbi.2014.09.024
- 23. N. Nakov, L. Bogdanovska, J. Acevska, J. Tonic-Ribarska, R. Petkovska A. Dimitrovska, L. Kasabova and D. Svinarov, High-throughput HPLC-MS/MS method for quantification of ibuprofen enantiomers in human plasma: Focus on investigation of metabolite interference, J. Chromatogr. Sci.54 (2016) 1820–1826; https://doi.org/10.1093/chromsci/bmw166
- 24. K. Jakovski, A. Kapedanovska Nestorovska, N. Labacevski and A. J. Dimovski, Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population of R. Macedonia, Pharmazie68 (2013) 893–898, https://doi.org/10.1691/ph.2013.3579
- 25. A. Kapedanovska Nestorovska, K. Jakovski, Z. Naumovska, Z. Sterjev, N. Matevska Geskovska, A. J. Dimovski and Lj. Suturkova, Allele frequency and genotype distribution of aldo keto reductase 1D1 (AKR1D1) rs1872930 genetic variant in a Macedonian population, Maced. Pharm. Bull. 64 (2018), in press.
- 26. C. Martínez, E. García-Martín, G. Blanco, F. J. Gamito, J. M. Ladero and J. A. Agúndez, The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects, Br. J. Clin. Pharmacol.59 (2005) 62–69; https://doi.org/10.1111/j.1365-2125.2004.02183.x
- 27. E. García-Martín, C. Martínez, B. Tabarés, J. Frías and J. A. Agúndez, Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms, Clin. Pharmacol. T her.76 (2004) 119–127; https://doi.org/10.1016/j.clpt.2004.04.006
- 28. D. Ochoa, R. Prieto-Pérez, M. Román, M. Talegón, A. Rivas, G. Galicia, F. Abad-Santos and T. Cabaleiro, Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers, Pharmacogenomics16 (2015) 939–948; https://doi.org/10.2217/pgs.15.40
- 29. R. López-Rodríguez, J. Novalbos, S. Gallego-Sandín, M. Román-Martínez, J. Torrado, J. P. Gisbert and F. Abad-Santos, Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers, Pharmacol. Res.58 (2008) 77–84; https://doi.org/10.1016/j.phrs.2008.07.004
- 30. M. Karazniewicz-Lada, M. Luczak and F. Glowka, Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes, Xenobiotica39 (2009) 476–485; https://doi.org/10.1080/00498250902862705
- 31. A. D. Rodrigues and T. H. Rushmore, Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences, Curr. Drug Metab.3 (2002) 289–309; https://doi.org/10.2174/1389200023337522
- 32. D. H. Solomon, M. E. Husni, P. A. Libby, N. D. Yeomans, A. M. Lincoff, T. F. Lϋscher, V. Menon, D. M. Brennan, L. M. Wisniewski, S. E. Nissen and J. S. Borer, The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: A secondary analysis of the PRECISION trial, Am. J. Med.130 (2017) 1415–1422.e4; https://doi.org/10.1016/j.amjmed.2017.06.028
- 33. N. Moore and J. M. Scheiman, Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesics, Postgrad. Med.130 (2018) 188–199; https://doi.org/10.1016/j.amjmed.2017.06.02